The selective inactivation of TNFR1 receptor by XPro1595 should thus result in a better safety profile, avoiding potential neurological problems and limiting drug-induced increased susceptibility to infections and cancer that are characteristics side effects of the non-selective TNF inhibitors. This evidence concerns the gene TNF and cancer.